K13
Conditions
Interventions
Group 1: Participants received ten consecutive weekly sessions of photodynamic therapy using 5% 5-aminolevulinic acid (ALA) gel applied topically to oral lesions. The gel was protected with an occlusi
Sponsors
Medical University of Bialystok
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: histopathologically confirmed oral lichen planus
Exclusion criteria
Exclusion criteria: systemic diseases that may present with oral lesions, smoking, pregnancy or lactation, and treatment of oral lesions within the previous six months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Lesion Surface Area Measurement of oral lichen planus lesion size using a PCPUNC15 periodontal probe. Lesions categorized as no lesion, =1 cm2, >1 cm2 and =3 cm2, or >3 cm2. [Time Frame: Baseline (T0), immediately after treatment (T1), 12 months (T2), and 48 months (T3) after therapy.] | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in REU Index (Reticulation-Erythema-Ulceration Score) Clinical severity of lesions assessed with the REU scoring system, which quantifies reticular, erythematous, and ulcerative components of oral lichen planus lesions. [Time Frame: Baseline (T0), immediately after treatment (T1), 12 months (T2), and 48 months (T3).] Change in Symptom Intensity (VAS Score) Patient-reported symptom severity, including pain and burning sensation, assessed with the Visual Analogue Scale (VAS; 0 = no symptoms, 10 = worst imaginable pain). [Time Frame: Baseline (T0), immediately after treatment (T1), 12 months (T2), and 48 months (T3).] | — |
Countries
Poland
Contacts
Public ContactMagdalena Sulewska
Medical University of Bialystok
Outcome results
None listed